At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 778 enrolled
Drug / intervention
Atogepant 30 mg +2 moredrug
Likely dose
Atogepant 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine (Progress)
In Brief
A Phase 3 clinical trial evaluating Atogepant 30 mg, Atogepant 60 mg, and 1 other intervention for Chronic Migraine. Completed, enrolled 778 participants across 150 sites in 17 countries.
Detailed Summary
This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesAustralia, Canada, China, Czechia, Denmark, France, Germany, Italy, Japan, Poland, Russia, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionJan 2022
TodayJul 2026
First PostedFeb 26, 2019
Enrollment StartMar 11, 2019
Primary CompletionJan 20, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.4 years ago
Interventions
Atogepant 30 mgdrug
Tablets containing 30 mg atogepant
Atogepant 60 mgdrug
Tablets containing 60 mg atogepant
Placebodrug
30 mg/60 mg tablets containing atogepant-matching placebo